Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphoma
Open Access
- 15 May 2020
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (6), 1714-1724
- https://doi.org/10.3324/haematol.2019.245860
Abstract
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a recently characterized T-cell malignancy that has raised significant patient safety concerns and led to worldwide impact on the implants used and clinical management of patients undergoing reconstructive or cosmetic breast surgery. Molecular signatures distinguishing BIA-ALCL from other ALCLs have not been fully elucidated and classification of BIA-ALCL as a WHO entity remains provisional. We performed RNA sequencing and gene set enrichment analysis comparing BIA-ALCLs to non-BIA-ALCLs and identified dramatic upregulation of hypoxia signaling genes including the hypoxia-associated biomarker CA9 (carbonic anyhydrase-9). Immunohistochemistry validated CA9 expression in all BIA-ALCLs, with only minimal expression in non-BIA-ALCLs. Growth induction in BIA-ALCL-derived cell lines cultured under hypoxic conditions was proportional to up-regulation of CA9 expression, and RNA sequencing demonstrated induction of the same gene signature observed in BIA-ALCL tissue samples compared to non-BIA-ALCLs. CA9 silencing blocked hypoxia-induced BIA-ALCL cell growth and cell cycle-associated gene expression, whereas CA9 overexpression in BIA-ALCL cells promoted growth in a xenograft mouse model. Furthermore, CA9 was secreted into BIA-ALCL cell line supernatants and was markedly elevated in human BIA-ALCL seroma samples. Finally, serum CA9 concentrations in mice bearing BIA-ALCL xenografts were significantly elevated compared to control serum. Together, these findings characterize BIA-ALCL as a hypoxia-associated neoplasm, likely attributable to the unique microenvironment in which it arises. These data support classification of BIA-ALCL as a distinct entity and uncover opportunities for investigating hypoxia-related proteins such as CA9 as novel biomarkers and therapeutic targets in this disease.Keywords
This publication has 48 references indexed in Scilit:
- Recent advances of immunohistochemistry for diagnosis of renal tumorsPathology International, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Carbonic Anhydrase IX Interacts with Bicarbonate Transporters in Lamellipodia and Increases Cell Migration via Its Catalytic DomainJournal of Biological Chemistry, 2012
- Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX InhibitorsCancer Research, 2011
- Breast implant‐associated, ALK‐negative, T‐cell, anaplastic, large‐cell lymphoma: Establishment and characterization of a model cell line (TLBR‐1) for this newly emerging clinical entityCancer, 2010
- Membrane-bound carbonic anhydrases are key pH regulators controlling tumor growth and cell migrationAdvances in Enzyme Regulation, 2009
- Hypoxia-inducible factor signaling in the development of tissue fibrosis.Cell Cycle, 2008
- Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancerBritish Journal of Cancer, 2007
- Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinomaLung Cancer, 2006
- Complications Leading to Surgery after Breast ImplantationNew England Journal of Medicine, 1997